Skip to main content

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

Bullock, Roger A., Touchon, Jacques, Bergman, Howard, Gambina, Giuseppe, He, Yunsheng, Rapatz, Gunter, Nagel, Jennifer, Lane, Roger (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Current Medical Research and Opinion, 21 (8). pp. 1317-1327. ISSN 0300-7995. (doi:10.1185/030079905X56565) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:12061)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication)
Official URL
http://dx.doi.org/10.1185/030079905X56565

Abstract

Objectives: Randomised controlled trials that directly compare cholinesterase inhibitors for the treatment of Alzheimer's disease have been characterised by significant methodological limitations. As a consequence, they have failed to establish whether there are differences between agents in this class. To help address this question, a double-blind, randomised, controlled, multicentre trial was designed to evaluate the efficacy and tolerability of cholinesterase inhibitor treatment in patients with moderate to moderately-severe Alzheimer's disease over a 2-year period.

Conclusions: Cholinesterase inhibitor treatment may offer continued therapeutic benefit for up to 2 years in patients with moderate AD. Although both drugs performed similarly on cognition and behaviour, rivastigmine may provide greater benefit in activities of daily living and global functioning.

Item Type: Article
DOI/Identification number: 10.1185/030079905X56565
Subjects: R Medicine
Divisions: Faculties > Sciences > Kent Institute of Medicine and Health Sciences (KIMHS)
Depositing User: M.P. Stone
Date Deposited: 05 Sep 2008 16:09 UTC
Last Modified: 28 May 2019 13:48 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/12061 (The current URI for this page, for reference purposes)
  • Depositors only (login required):